ArticleEuropean child & adolescent psychiatry2022
Response (minimum clinically relevant change) in ASD symptoms after an intervention according to CARS-2: consensus from an expert elicitation procedure.
Article in European child & adolescent psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- The Efficacy and Safety of Bumetanide in Children with Autism Spectrum Disorder: An Updated Meta-analysis.European child & adolescent psychiatry · 2026Pooled it
- A Mitochondrial Supplement Improves Function and Mitochondrial Activity in Autism: A Double-Blind Placebo-Controlled Cross-Over Trial.International journal of molecular sciences · 2025Trial
- Effectiveness of a Robot-Assisted Psychological Intervention for Children with Autism Spectrum Disorder.Journal of autism and developmental disorders · 2024Trial
- Low-Dose Sevoflurane Restores Prefrontal Excitatory/Inhibitory Balance and Improves Autism-Like Social Behavior: A Preclinical and Pilot Clinical Study.Drug design, development and therapy · 2026Article
- Potential Benefits of a Noninvasive Neuromodulation Protocol in Autism Spectrum Disorder with Multiple Comorbidities: A Case Report.Pediatric reports · 2025Article
- Transcranial photobiomodulation in children aged 2-6 years: a randomized sham-controlled clinical trial assessing safety, efficacy, and impact on autism spectrum disorder symptoms and brain electrophysiology.Frontiers in neurology · 2024Article
- Donepezil as a new therapeutic potential in KCNQ2- and KCNQ3-related autism.Frontiers in cellular neuroscience · 2024Article
- The fecal microbiota from children with autism impact gut metabolism and learning and memory abilities of honeybees.Frontiers in microbiology · 2023Article
- Olink proteomics profiling platform reveals non-invasive inflammatory related protein biomarkers in autism spectrum disorder.Frontiers in molecular neuroscience · 2023Article
- Corneal confocal microscopy demonstrates sensory nerve loss in children with autism spectrum disorder.PloS one · 2023Article
- Machine learning-based ABA treatment recommendation and personalization for autism spectrum disorder: an exploratory study.Brain informatics · 2022Article
- Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomised, parallel-group pilot clinical study.BMJ neurology open · 2022Article
- Integrative treatment program for the treatment of children with autism spectrum disorder: A prospective observational case series.Frontiers in neurology · 2022Article
- Ketogenic Dietary Therapies in Patients with Autism Spectrum Disorder: Facts or Fads? A Scoping Review and a Proposal for a Shared Protocol.Nutrients · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lack of consensual measures to monitor core change in Autism Spectrum Disorder (ASD) or response to interventions leads to difficulty to prove intervention efficacy on ASD core symptoms. There are no universally accepted outcome measures developed for measuring changes in core symptoms. However, the CARS (Childhood Autism Rating Scale) is one of the outcomes recommended in the EMA Guideline on the clinical development of medicinal products for the treatment of ASD. Unfortunately, there is currently no consensus on the response definition for CARS among individuals with ASD. The aim of this elicitation process was to determine an appropriate definition of a response on the CARS2 scale for interventions in patients with Autism Spectrum Disorder (ASD). An elicitation process was conducted following the Sheffield Elicitation Framework (SHELF). Five experts in the field of ASD and two experts in expert knowledge elicitation participated in an 1-day elicitation workshop. Experts in ASD were previously trained in the SHELF elicitation process and received a dossier of scientific evidence concerning the topic. The response definition was set as the mean clinically relevant improvement averaged over all patients, levels of functioning, age groups and clinicians. Based on the scientific evidence and expert judgment, a normal probability distribution was agreed to represent the state of knowledge of this response with expected value 4.03 and standard deviation 0.664. Considering the remaining uncertainty of the estimation and the available literature, a CARS-2 improvement of 4.5 points has been defined as a threshold to conclude to a response after an intervention. A CARS-2 improvement of 4.5 points could be used to evaluate interventions' meaningfulness in indivudals. This initial finding represents an important new benchmark and may aid decision makers in evaluating the efficacy of interventions in ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.